Mattson acquires Hyde Park Group, explores the Ozempic effect

Mattson expands to Chicago with acquisition of Hyde Park Group, explores the Ozempic effect

Two packages of 5 dosing pens each of a fictitious Semiglutin drug used for weight loss (antidiabetic medication or anti-obesity medication) on a blue transparent background. Fictitious package design

GLP-1 drugs are “going to be a big disruptor for the food industry,” says Dr. Justin Shimek at California-based product innovation firm Mattson, which is expanding to the Midwest with the acquisition of Hyde Park Group.